Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Citius Pharmaceuticals Inc (NASDAQ: CTXR) closed the day trading at $1.15 down -5.74% from the previous closing price of $1.22. In other words, the price has decreased by -$5.74 from its previous closing price. On the day, 0.56 million shares were traded. CTXR stock price reached its highest trading level at $1.24 during the session, while it also had its lowest trading level at $1.1.
Ratios:
For a better understanding of CTXR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.14 and its Current Ratio is at 0.47. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On November 30, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTXR now has a Market Capitalization of 19564030 and an Enterprise Value of 17858924.
Stock Price History:
The Beta on a monthly basis for CTXR is 1.43, which has changed by -0.91320753 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, CTXR has reached a high of $15.25, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is -21.78%, while the 200-Day Moving Average is calculated to be -40.24%.
Shares Statistics:
Over the past 3-months, CTXR traded about 2.69M shares per day on average, while over the past 10 days, CTXR traded about 719700 shares per day. A total of 17.01M shares are outstanding, with a floating share count of 16.04M. Insiders hold about 5.74% of the company’s shares, while institutions hold 5.46% stake in the company. Shares short for CTXR as of 1755216000 were 658545 with a Short Ratio of 0.24, compared to 1752537600 on 1121886. Therefore, it implies a Short% of Shares Outstanding of 658545 and a Short% of Float of 3.9899999999999998.
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Citius Pharmaceuticals Inc (CTXR) in the stock market.
Analysts are recommending an EPS of between -$2.08 and -$2.08 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is $1.9, with 1.0 analysts recommending between $1.9 and $1.9.
Revenue Estimates
For the next quarter, 2 analysts are estimating revenue of $15.59M. There is a high estimate of $15.59M for the next quarter, whereas the lowest estimate is $15.59M.
Based on 2 analysts’ estimates, the company’s revenue will be $73.04M in the next fiscal year. The high estimate is $78.29M and the low estimate is $67.78M.
